Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations
V Dussupt, RS Sankhala, L Mendez-Rivera… - Nature …, 2021 - nature.com
Prevention of viral escape and increased coverage against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) variants of concern require therapeutic monoclonal …
syndrome coronavirus 2 (SARS-CoV-2) variants of concern require therapeutic monoclonal …
SARS-CoV-2 neutralizing antibodies for COVID-19 prevention and treatment
D Li, GD Sempowski, KO Saunders… - Annual review of …, 2022 - annualreviews.org
Prophylactic and therapeutic drugs are urgently needed to combat coronavirus disease
2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV …
2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV …
An engineered bispecific human monoclonal antibody against SARS-CoV-2
Z Li, S Li, G Zhang, W Peng, Z Chang, X Zhang… - Nature …, 2022 - nature.com
The global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic
requires effective therapies against coronavirus disease 2019 (COVID-19), and neutralizing …
requires effective therapies against coronavirus disease 2019 (COVID-19), and neutralizing …
Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections
The ongoing pandemic of coronavirus disease 2019 (COVID-19) is caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). Neutralizing antibodies against SARS …
respiratory syndrome coronavirus 2 (SARS-CoV-2). Neutralizing antibodies against SARS …
Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain
X Chi, X Liu, C Wang, X Zhang, X Li, J Hou… - Nature …, 2020 - nature.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spreads worldwide and
leads to an unprecedented medical burden and lives lost. Neutralizing antibodies provide …
leads to an unprecedented medical burden and lives lost. Neutralizing antibodies provide …
Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy
Understanding how potent neutralizing antibodies (NAbs) inhibit SARS-CoV-2 is critical for
effective therapeutic development. We previously described BD-368-2, a SARS-CoV-2 NAb …
effective therapeutic development. We previously described BD-368-2, a SARS-CoV-2 NAb …
The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2
AL Cathcart, C Havenar-Daughton, FA Lempp, D Ma… - biorxiv, 2021 - biorxiv.org
ABSTRACT VIR-7831 and VIR-7832 are dual action monoclonal antibodies (mAbs)
targeting the spike glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS …
targeting the spike glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS …
SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes
coronavirus disease 2019 (Covid-19), which is most frequently mild yet can be severe and …
coronavirus disease 2019 (Covid-19), which is most frequently mild yet can be severe and …
A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein
C Kim, DK Ryu, J Lee, YI Kim, JM Seo, YG Kim… - Nature …, 2021 - nature.com
Vaccines and therapeutics are urgently needed for the pandemic caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we screen human monoclonal …
respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we screen human monoclonal …
Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes
D Fu, G Zhang, Y Wang, Z Zhang, H Hu, S Shen… - PLoS …, 2021 - journals.plos.org
The ongoing Coronavirus Disease 2019 (COVID-19) pandemic caused by Severe Acute
Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) threatens global public health and …
Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) threatens global public health and …